688670.SH
Jiangsu gdk Biotechnology Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 12.99
+2.44%Oct 30, 2026, 11:21 UTC
Jindike reported revenue of 920,500 yuan and a net loss of 89.3806 million yuan for the first three quarters of 2026.
Source:Oct 30, 2026, 11:21 UTC
Jindike reported third-quarter 2026 revenue of 9,536.38 yuan, down 99.99% year over year, and a net loss of 38.3102 million yuan.
Source:Oct 9, 2026, 10:49 UTC
China’s National Medical Products Administration granted Jindike a registration certificate for its trivalent influenza vaccine, in a 0.5 ml-per-dose specification, valid through September 28, 2031.
Source:Aug 20, 2026, 12:23 UTC
Jindike announced its H1 2026 results: revenue fell 74.15% year-on-year to 0.9109 million yuan, and net loss attributable to shareholders widened to 51.0704 million yuan from 39.6531 million yuan a year earlier.
Source: